Catalyst Pharmaceuticals, Inc

Short Term Long Term Short Term Comparison Long Term Comparison

CPRX
1d-1.46%
1w-7.41%
1m-16.72%
1y166.15%
CPRX
1y166.15%
5y356.93%
10y2,937.25%
20y0.00%

Bitcoin
-2.01%
1.39%
40.01%
-36.91%
Bitcoin
-36.91%
164.38%
110,540.00%
0.00%

Ethereum
-1.04%
3.32%
36.37%
-38.45%
Ethereum
-38.45%
81.05%
0.00%
0.00%

Gold
0.08%
0.07%
4.90%
7.04%
Gold
7.04%
44.70%
15.60%
420.47%

Silver
-0.14%
0.20%
-2.70%
5.39%
Silver
5.39%
41.13%
-25.93%
387.74%

Apple
0.79%
1.02%
11.93%
-16.81%
Apple
-16.81%
281.16%
-67.94%
66,427.90%

Amazon
1.96%
5.98%
25.18%
-30.19%
Amazon
-30.19%
47.07%
-60.32%
9,524.71%

Microsoft
1.99%
1.92%
5.39%
-18.61%
Microsoft
-18.61%
192.43%
804.94%
1,601.52%

S&P 500
1.47%
2.68%
9.30%
-6.65%
S&P 500
-6.65%
51.32%
176.23%
385.84%

Dow & Jones
-0.11%
0.22%
2.77%
-3.01%
Dow & Jones
-3.01%
33.44%
143.07%
319.91%

ATH

ATH Price$21.05
ATH Date2023-01-13
% since ATH-26.41%
% to ATH35.89%

ATL

ATL Price$0.39
ATL Date2012-11-12
% from ATL3,841.48%
Last Low Price$14.76
Last Low Date2023-01-23
% From Last Low4.95%

IPO

IPO Price$6.00
% Current ROI USD258.17%
ATH Price$21.05
% ROI ATH 535,623.41%

Graph takes few seconds to load...

Key Data

Current price	$15.49
Sector	Healthcare
Industry	Biotechnology
Today's High/Low	$15.96/$15.25
Volume	2,313,048.00
Previous Close	$15.72
52 Week High/Low	$22.11/$5.58
Market Cap	1,612,059,776.00
P/E Ratio	24.9839
Forward P/E 1 Yr.	$19.31
Earnings Per Share(EPS)	$1.21
Annualized Dividend	$0

$15.49

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States.
It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS) and myasthenia gravis; and Ruzurgi for the treatment of pediatric LEMS patients.
The company also develops Firdapse for the treatment of anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3.
It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets.
The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Annual Data \| Millions of US $ except per share data	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31	2005-12-31	2004-12-31
Cash on hand	$94.52	$53.48	$84.01	$40.41	$58.40	-	-	-	-	-	-	-	-	-	-	-
Receivables	$10.54	-	-	-	-	$3.50	-	-	-	-	-	-	-	-	-	-
Inventory	$1.96	$0.06	$0	$0	$0	$0	$0	$0	$0	-	-	-	-	-	-	-
Pre-Paid Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Current Assets	$0.52	$0.27	$0.06	$0.04	$5.22	$1.05	$1.61	$1.31	$0.20	$0.17	$0.11	$0.14	$0.52	$0.07	-	-
Total Current Assets	$111.36	$55.19	$85.19	$41.45	$59.90	$43.83	$25.32	$0	$0	-	-	-	-	-	-	-
Property, Plant, And Equipment	$1	$0.25	$0.19	$0.24	$0.19	$0.07	$0.04	$0.05	$0.01	$0.05	$0.07	$0.10	$0.13	$0.02	$0400000	$0100000
Long-Term Investments	$0	$5.01	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Goodwill And Intangible Assets	-	-	$0	$0	$0	$0	$0	$0	$0	-	-	-	-	-	-	-
Other Long-Term Assets	$0888800	$0888800	$0888800	$0888800	$0888800	$0900000	$0900000	$0900000	$0900000	$0.01	$0.01	$0.02	$0.02	$0.01	$0.01	-
Total Long-Term Assets	$1.01	$5.26	$0.20	$0.25	$0.20	-	-	-	-	-	-	-	-	-	-	-
Total Assets	$112.38	$60.45	$85.39	$41.71	$60.10	$43.91	$25.37	$16.79	$6.25	$5.83	$7.97	$12.03	$16.68	$20.62	$0.79	$0.19
Total Current Liabilities	$24.10	$9.51	$4.27	$2.09	$3.44	$5.86	$2.14	$1.65	$0.83	$0.30	$0.29	$1.43	$0.30	$0.77	$0.34	$0.07
Long Term Debt	-	-	$0	$0	$0	$0	$0	$0	$0	-	-	-	-	-	-	-
Other Non-Current Liabilities	-	$0.15	$0.16	$0.30	$1.18	$2.81	$1.84	$0.52	$1.65	$0.01	$0.05	$0.04	$0.05	-	-	-
Total Long Term Liabilities	$0.65	$0.15	$0.16	$0.30	$1.18	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	$24.75	$9.67	$4.42	$2.40	$4.63	$8.67	$3.98	$2.17	$2.49	$0.31	$0.35	$1.47	$0.36	$0.77	$0.34	$0.07
Common Stock Net	$0.10	$0.10	$0.10	$0.08	$0.08	$0.07	$0.05	$0.04	$0.03	$0.02	$0.02	$0.01	$0.01	$0.01	$0.07	$0.03
Retained Earnings (Accumulated Deficit)	$-128.69	$-160.56	$-126.56	$-108.15	$-90.08	$-69.84	$-54.33	$0	$0	-	-	-	-	-	-	-
Comprehensive Income	-	-	$0	$0	$0	$0	$0	$0	$0	-	-	-	-	-	-	-
Other Share Holders Equity	$0950500	$-0.02	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Share Holder Equity	$87.63	$50.78	$80.96	$39.31	$55.48	$35.24	$21.39	$14.62	$3.76	$5.52	$7.62	$10.56	$16.32	$19.85	$0.45	$0.12
Total Liabilities And Share Holders Equity	$112.38	$60.45	$85.39	$41.71	$60.10	-	-	-	-	-	-	-	-	-	-	-

Annual Data \| Millions of US $ except per share data	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31	2005-12-31	2004-12-31
Revenue	$102.31	$0.50	$0	$0	$0	$0	$0	$0	$0	$0.49	-	-	-	-	-	-
Cost Of Goods Sold	$14.76	$19.92	$11.38	$0	$0	$0	$0	$0	$6.04	$4.49	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Research And Development Expenses	$18.84	$19.92	$11.38	$11.37	$11.80	$10.12	$8.10	$2.66	$3.38	$2.31	$5.10	$8.71	$2.99	$0.99	$1.46	$0.38
SG&A Expenses	$36.88	$15.88	$7.30	$7.91	$8.60	$4.47	$2.21	$2.56	$2.70	-	$7.25	$10.86	$5.01	$2.90	$1.82	$0.54
Other Operating Income Or Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	$70.48	$35.80	$18.68	$19.28	$20.40	$14.59	$10.31	$5.22	$6.08	-	-	-	-	-	-	-
Operating Income	$31.82	$-35.30	$-18.68	$-19.28	$-20.40	$-14.59	$-10.31	$-5.22	$-6.08	-	-	-	-	-	-	-
Total Non-Operating Income/Expense	$1.59	$1.29	$0.27	$1.21	$0.17	$-0.92	$-1.84	$1.14	$-0.31	-	-	-	-	-	-	-
Pre-Tax Income	$33.41	$-34351400	$-18.41	$-18.07	$-20.23	$-15.51	$-12.15	$-4.08	$-6.39	-	-	-	-	-	-	-
Income Taxes	$1.53	$0	$0	$0	$0	$0	$0	$0	$0	-	-	-	-	-	-	-
Income After Taxes	$1.53	$0	$0	$0	$0	$0	$0	$0	$0	-	-	-	-	-	-	-
Other Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income From Continuous Operations	$31.88	$-34351400	$-18.41	$-18.07	$-20.23	$-15.51	$-12.15	$-4.08	$-6.39	-	-	-	-	-	-	-
Income From Discontinued Operations	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	$31.88	$-34351400	$-18.41	$-18.07	$-20.23	$-15.51	$-12.15	$-4.08	$-6.39	-	-	-	-	-	-	-
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBIT	$31.82	$-35.30	$-18.68	$-19.28	$-20.40	$-14.59	$-10.31	$-5.22	$-6.08	-	-	-	-	-	-	-
Basic Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares Outstanding	$106	$103	$102.55	$83	$81	$64	$45	$30	$22	$19	$15	$13	$13	$8	$6	$6
Basic EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EPS - Earnings Per Share	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Annual Data \| Millions of US $ except per share data	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31	2005-12-31	2004-12-31
Net Income/Loss	$31.88	$-34351400	$-18.41	$-18.07	$-20.23	$-15.51	$-12.15	$-4.08	$-6.39	-	-	-	-	-	-	-
Total Depreciation And Amortization - Cash Flow	$0.30	$0.04	$0.05	$0.04	$0.03	$0.03	$0.02	$0.01	$0.04	-	-	-	-	-	-	-
Change In Accounts Receivable	$-10.54	$-10.54	$-10.54	$-10.54	$0	$0	$0	$0	$0.13	-	$0.01	$0.05	$0.02	-	-	-
Change In Inventories	$-1.90	$-0.06	$-0.06	$-0.06	$-0.06	$0	$0	$0	$0	-	-	-	-	-	-	-
Cash Flow From Operating Activities	$34.61	$-25.70	$-13.74	$-17.96	$-18.02	$-12.94	$-9.88	$-5.14	$-4.99	-	-	-	-	-	-	-
Cash Flow From Investing Activities	$37.22	$-15.08	$-0395800	$3.55	$-0649900	$-8.74	$-7.50	$-14.06	$-0362000	-	-	-	-	-	-	-
Debt Issuance/Retirement Net - Total	-	-	-	-	-	-	-	$5	-	-	-	-	-	-	-	-
Total Common And Preferred Stock Dividends Paid	-	-	$0	$0	$0	$0	$0	$0	$0	-	-	-	-	-	-	-
Financial Activities - Other	-	$-0444800	-	$-0.01	$-0.01	$-0.01	-	-	-	-	-	-	-	-	-	-
Cash Flow From Financial Activities	$1.12	$0.29	$57.35	$0.07	$37.16	$28.56	$18.18	$14.58	$5.54	$1.46	$3.70	$4.08	-	$20.86	$1.05	-
Net Cash Flow	$72.95	$-40.94	$43.60	$-14.34	$19.14	$6.88	$0.81	$-4.62	$0.55	-	-	-	-	-	-	-
Common Stock Dividends Paid	-	-	$0	$0	$0	$0	$0	$0	$0	-	-	-	-	-	-	-